CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Spero Investors of a Lead Plaintiff Deadline of July 25, 2022

NEW YORK, July 11, 2022

The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between October 28, 2021 and May 2, 2022.

If you suffered a loss on your investment in Spero, contact us about potential recovery by using the link below. There is no cost or obligation to you.

https://www.wongesq.com/pslra-1/spero-therapeutics-inc-loss-submission-form?prid=29656&wire=4

ABOUT THE ACTION: The class action against Spero includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) the data submitted in support of the New Drug Application ("NDA") for the Company's product candidate, Tebipenem HBr, were insufficient to obtain  approval from the U.S. Food and Drug Administration ("FDA"); (ii) accordingly, it was unlikely that the FDA would approve the Tebipenem HBr NDA in its current form; (iii) the foregoing would necessitate a significant workforce reduction and restructuring of Spero's operations; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

DEADLINE: July 25, 2022

Aggrieved Spero investors only have until July 25, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.